|
LIVE WEBINAR: Tuesday, August 8, 2023, 5:00 PM – 6:00 PM Eastern Time
Inside the Issue: Optimizing the Management of Metastatic Pancreatic CancerA CME/MOC-Accredited Live Webinar Register for this complimentary event with the “Register Now” button above, Join us on Tuesday, August 8th for this CME/MOC-accredited webinar Faculty
Eileen M O’Reilly, MD Winthrop Rockefeller Endowed Chair in Medical Oncology Section Head, Hepatopancreaticobiliary and Neuroendocrine Cancers Co-Director, Medical Initiatives David M Rubenstein Center for Pancreatic Cancer Research Chair Human Research Protection Program and IRB Attending Physician, Member Memorial Sloan Kettering Cancer Center Professor of Medicine Weill Cornell Medical College New York, New York
Zev Wainberg, MD, MSc
Co-Director, GI Oncology Program Director of Early Phase Clinical Research Jonsson Comprehensive Cancer Center UCLA School of Medicine Los Angeles, California Moderator Neil Love, MD Research To Practice Miami, Florida Tuesday, August 8, 2023 Topics to Be Discussed
Target Audience
CE Credit FACULTY — The following faculty reported relevant financial relationships with ineligible entities: Dr O'Reilly — Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Autem Therapeutics, Berry Genomics, BioNTech SE, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Eisai Inc, Exelixis Inc, FibroGen Inc, Genentech, a member of the Roche Group, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Merck, Merus BV, Neogene Therapeutics, Novartis, Servier Pharmaceuticals LLC, Tempus, Thetis Pharmaceuticals, Vector Pharma, Yiviva; Contracted Research: Agenus Inc, Arcus Biosciences, AstraZeneca Pharmaceuticals LP, BioNTech SE, Bristol Myers Squibb, Digestive Care Inc, Elicio Therapeutics, Genentech, a member of the Roche Group, Helsinn Healthcare SA, Puma Biotechnology Inc, QED Therapeutics, Yiviva; Nonrelevant Financial Relationship: Parker Institute for Cancer Immunotherapy. Dr Wainberg — Advisory Committee and Consulting Agreements: Amgen Inc, Arcus Biosciences, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Lilly, Merck, Novartis, Roche Laboratories Inc, Seagen Inc, Takeda Pharmaceuticals USA Inc; Contracted Research: Arcus Biosciences, Bristol Myers Squibb; Data and Safety Monitoring Board/Committee: Daiichi Sankyo Inc, Pfizer Inc. SERIES MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc. SURVEY PARTICPANTS — Tanios Bekaii-Saab, MD — Consulting Agreements (to Institution): Arcus Biosciences, Bayer HealthCare Pharmaceuticals, Eisai Inc, Genentech, a member of the Roche Group, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Merck, Merck KgaA, Merus BV, Pfizer Inc, Seagen Inc, Servier Pharmaceuticals LLC; Consulting Agreements (to Self): AbbVie Inc, Aptitude Health, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Caladrius Biosciences, Celularity, Daiichi Sankyo Inc, Deciphera Pharmaceuticals Inc, Exact Sciences Corporation, Exelixis Inc, Foundation Medicine, GSK, Illumina, Janssen Biotech Inc, Kanaph Therapeutics, Natera Inc, Sanofi, Sobi, Stemline Therapeutics Inc, Treos Bio Ltd, Zai Lab; Data and Safety Monitoring Board/Committee: 1Globe Health Institute, AstraZeneca Pharmaceuticals LP, Eisai Inc, Exelixis Inc, FibroGen Inc, Merck, Suzhou Kintor; Inventions/Patents: WO/2018/183488 licensed to Imugene, WO/2019/055687 licensed to Recursion; Research Funding (to Institution): AbGenomics, Agios Pharmaceuticals Inc, Arcus Biosciences, Arrys Therapeutics, a wholly owned subsidiary of Kyn Therapeutics, Atreca, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Eisai Inc, Genentech, a member of the Roche Group, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Lilly, Merus BV, Mirati Therapeutics Inc, Novartis, Pfizer Inc, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc; Scientific Advisory Board: Artiva Biotherapeutics Inc, Immuneering Corporation, Imugene, Panbela Therapeutics Inc, Replimune, Xilis; Nonrelevant Financial Relationship: MJH Life Sciences, Pancreatic Cancer Action Network, UpToDate, The Valley Hospital. Kristen K Ciombor, MD, MSCI —Advisory Committee: Bayer HealthCare Pharmaceuticals, Exelixis Inc, Incyte Corporation, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Personalis, Pfizer Inc, Replimune, Seagen Inc; Consulting Agreements: Merck, Pfizer Inc; Contracted Research: Array BioPharma Inc, a subsidiary of Pfizer Inc, Bristol Myers Squibb, Calithera Biosciences, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Incyte Corporation, Merck, NuCana, Pfizer Inc, Seagen Inc. Wells A Messersmith, MD — Consulting Agreements: Cardiff Oncology, Istari Oncology; Contracted Research: ALX Oncology, AStar EDDC, BeiGene Ltd, CanBas Co Ltd, Exelixis Inc, Fate Therapeutics, Pfizer Inc, PureTech Health, Mirati Therapeutics Inc, Rascal Therapeutics; Data and Safety Monitoring Board/Committee: Amgen Inc, QED Therapeutics, Zymeworks Inc; Unpaid Advisory Board: Pfizer Inc, Takeda Pharmaceuticals USA Inc; Nonrelevant Financial Relationship: Criterium. Philip A Philip, MD, PhD, FRCP — Advisory Committee: Bayer HealthCare Pharmaceuticals, Ipsen Biopharmaceuticals Inc, Merus BV, Novocure Inc, Pfizer Inc, Seagen Inc, Servier Pharmaceuticals LLC; Consulting Agreements: BioNTech SE, Totus Medicines; Contracted Research: Taiho Oncology Inc; Data and Safety Monitoring Board/Committee: Cyclacel Pharmaceuticals Inc, Oncolytics Biotech Inc; Speakers Bureau: Incyte Corporation, Servier Pharmaceuticals LLC. Michael Pishvaian, MD, PhD — Advisory Committee: Astellas, TriSalus Life Sciences; Consulting Agreements: AstraZeneca Pharmaceuticals LP, IDEAYA Biosciences, Merck, Merus BV, Novartis, Pfizer Inc, Seagen Inc; Contracted Research: Amgen Inc, Arcus Biosciences, Astellas, BioMed Valley Discoveries, Boehringer Ingelheim Pharmaceuticals Inc, Hutchison MediPharma, IDEAYA Biosciences, Merck, Novartis, Pfizer Inc, RenovoRx, Repare Therapeutics, Seagen Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, Tizona Therapeutics Inc; Nonrelevant Financial Relationship: Perthera (stock ownership). Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose. SupporterThis activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Ipsen Biopharmaceuticals Inc, Merck, and Novocure Inc. |